
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology is advancing a best-in-class immunotherapy agent capable of achieving market-leading share across the NMIBC space. With updates on their Phase 3 PIVOT-006 trial timing and completing the cretoBLA in HR-NMIBC in 4Q, the prospects for CG Oncology look positive and the company's financials show increasing spend with a strong cash position.
Bears say
CG Oncology is a clinical biopharmaceutical company that is developing an intravesically delivered immunotherapy agent for bladder cancer. While they have promising trials and potential for significant revenue and market potential in the future, their main focus, PIVOT-006, is facing challenges and their pipeline additions may not be enough to outweigh any setbacks. It is important to closely monitor their trial data and future developments in order to have a more accurate outlook on the company's potential success in the competitive bladder cancer market.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares